Check the brakes on IRF4!
In this issue of Blood, Chakraborty et al1 uncover a novel mechanism of control of the transcription factor IRF4. They show that BCL7A can act as a tumor s
Related Articles
Can we harmonize classification of TP53 mutant MDS/AML?
In this issue of Blood Advances, Shah et al1 provide an evidence-based proposal to harmonize the classification of TP53 mutant myelodysplastic neoplasms (M
Silence of the myeloma clones: GPRC5D epigenetic regulation
In this issue of Blood, Ma et al1 report on the loss of G protein–coupled receptor, class C, group 5, member D (GPRC5D) expression post–anti-GPRC5D…
Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia
Care for patients with chronic lymphocytic leukemia has been revolutionized in the last decade as Bruton tyrosine kinase inhibitors and the B-cell lymphoma
Throwing the microbiome out with the bathwater
In this issue of Blood Advances, Darwin et al1 review a wide-ranging body of preclinical and early clinical studies that highlight the impact of antibiotic
Younger haplo-donors improve older patient survival outcomes
In this issue of Blood Advances, Nagayama et al1 report that patients aged ≥50 years who receive haploidentical (haplo) stem cell transplantation using pos
COVID-19 and CLL in Sweden: lessons learned?
In this issue of Blood Advances, Hedberg et al1 describe the impact of COVID-19 in Sweden in patients with chronic lymphocytic leukemia (CLL) comparing the
TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation
Key PointsPatients with TP53-mutated AML/MDS represent a unique and heterogeneous high-risk group that should not be treated as 1 single entity.Transplant
Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury
Key PointsEarly use of daratumumab combinations in patients with MM admitted with kidney injury rapidly reduces sFLCs.Early initiation of daratumumab combi